Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ayers

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
JACC. Basic to Translational Science|April 29, 2024
Pulsatile ECMO: The Future of Mechanical Circulatory Support for Severe Cardiogenic ShockDouglas E Vincent, Nader Moazami, David D'Alessandro, et al.
Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.
Nature Communications|April 27, 2023
Sediment delivery to sustain the Ganges-Brahmaputra delta under climate change and anthropogenic impactsJessica L Raff, Steven L Goodbred, Jennifer L Pickering, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
JCI Insight|March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
JCI Insight|April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Advances|August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional seriesNarendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
Blood Advances|May 12, 2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyAdam S Zayac, Daniel J Landsburg, Mitchell E Hughes, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
JACC. Basic to Translational Science|April 29, 2024
Pulsatile ECMO: The Future of Mechanical Circulatory Support for Severe Cardiogenic ShockDouglas E Vincent, Nader Moazami, David D'Alessandro, et al.
Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.
Nature Communications|April 27, 2023
Sediment delivery to sustain the Ganges-Brahmaputra delta under climate change and anthropogenic impactsJessica L Raff, Steven L Goodbred, Jennifer L Pickering, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
JCI Insight|March 5, 2019
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
JCI Insight|April 20, 2018
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myelomaAlfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, et al.
Blood Advances|January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsPallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Blood Advances|August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional seriesNarendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
Blood Advances|May 12, 2023
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective studyAdam S Zayac, Daniel J Landsburg, Mitchell E Hughes, et al.
Pageof 19